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Morbidity from calciﬁc aortic valve disease (CAVD) is increasing. Recent studies suggest early reversible changes involv-
ing inﬂammation and neoangiogenesis. We hypothesized that microcalciﬁcations, chemokines, and growth factors are present
in unaﬀected regions of calciﬁc aortic valves. We studied aortic valves from 4 patients with CAVD and from 1 control, using
immunohistochemistry, scanning electron microscopy, and infrared spectrography. We revealed clusters of capillary neovessels
in calciﬁed (ECC), to a lesser extent in noncalciﬁed (ECN) areas. Endothelial cells proved constant expression of SDF-1 in
ECC, ECN, and endothelial cells from valvular surface (ECS). Its receptor CXCR4 was expressed in ECC. IL-6 expression
correlated with CXCR4 staining and presence of lymphocytes. VEGF was expressed by ECS, its receptor by ECC and ECN.
Crystallineultrastructures werefoundonthesurfaceofhistologicallynoncalciﬁedareas(HNCAs),spectrography revealed calcium
hydroxylapatite. Our results demonstrate that crystalline ultrastructures are present in HNCAs, undergoing neoangiogenesisin an
inﬂammatorycontext. These alterations could be an early witness of disease and an opening to therapy.
1.Introduction
Calciﬁc aortic valve disease (CAVD) is the most common
valvular lesion in Western countries and the major cause of
aortic valve replacement. It is associated with a higher death
risk from cardiovascular causes which is increased up to 50
per cent, even in the absence of a hemodynamically signif-
icant obstruction [1, 2]. With an aging population, CAVD
is becoming an important public health problem. Hitherto,
a cure for symptomatic calciﬁc aortic valve disease relies
entirely within surgical procedures with valve replacement.
Until recently, the concept that CAVD is a degenerative
and unmodiﬁable process basically induced by long-lasting
mechanical stress was generally accepted [3, 4]. Interestingly
recent studies suggest that valvular changes might not be an
unmodiﬁable degenerative disease but rather a dynamic
process involving inﬂammation, lipidinﬁltration, dystrophic
calciﬁcation, and endothelial dysfunction [5–7].
Chemokinesandgrowthfactorsplayanimportantrolein
several pathophysiological processes such as inﬂammation
and immunity. Chemokine receptor CXCR4 is expressed
on monocytes, B-lymphocytes, and most T cells [8–10].
It has been determined that CXCR4, which is present on
many diﬀerent types of cells, is activated by only one ligand,
stromal derived factor 1 (SDF-1) and mediates several dif-
ferent activities such as chemotaxis, adhesion, proliferation,2 Cardiology Research and Practice
survival, and, in some cells, apoptosis [11–13]. Activa-
tion of CXCR4 on lymphocytes and monocytes stimulates
chemotaxis, resulting in recruitment to sites of immune and
inﬂammatory reactions. Hematopoieticand endothelialpro-
genitor cells express CXCR4, and release of SDF-1 by bone
marrow stromal cells mediates sequestration and homing
of these progenitor cells to the bone marrow [14, 15]. Vice
versa, SDF-1 has also been implicated in revascularization
of ischemic hind limbs through recruitment of CXCR4+
hemangiocytes [16, 17],and, recently, SDF-1and its receptor
CXCR4havebeenshowntosupportdevelopmentofvascular
blood supply within inﬂammatory atherosclerotic plaques
[18]. On the other hand some vascular growth factors, in
particular VEGF and its receptors (VEGFR1 and 2), are
known to be involved in the evolution of malignancies,
intraocularneovasculardisorders,andatheroscleroticplaque
formation [19]. Pathological neoangiogenesis—whether in
thecontextofinﬂammation orcancer—ispartlyputontothe
account of VEGF/VEGFR signalling [20]. We hypothesized
thatSDF-1and VEGF might act as regulators ofangiogenesis
within primarily concerned valves, depending on their
expression and presence of their corresponding receptors on
endothelial cells.
Due to routine experience with minimal valvular altera-
tionsincludingdiscretecalciﬁcationandassociatedcapillary-
likeneovessels, we havebeeninterested inpossible early stage
changes of clinically silent and macroscopically inconspicu-
ous valve areas/valves. We therefore hypothesized that early
ﬁbrous remodeling and neoangiogenesis within aortic valves
could be initiated by ultrasctructural calciﬁc alterations.
2.Methods
Tissue samples corresponding to aortic valve resections were
collected from patients undergoing surgical treatment for
CAVD (n = 4) and aortic insuﬃciency due to aortic arch
aneurysms (n = 1) in the Department of Cardiac Surgery
(Hˆ opital de la Piti´ e-Salpˆ etri` ere, Paris). After resection,
specimens were ﬁxed in formalin and dissected. Half of the
specimens were processed to paraﬃn blocks and serially
sectioned at 3μm thickness. Slides were stained with haema-
toxylin, eosin, and saﬀron. The other half was discriminated
into calciﬁed and noncalciﬁed areas and eventually inserted
into X-ray permeable kapton ﬁlm for submission to X-ray
ﬂuorescence and X-ray diﬀraction experiments.
Each sample was investigated by FT-IR spectroscopy
using a Fourier transform infrared spectrometer Bruker
IFS25 (Bruker Spectrospin, Wissembourg, France) between
4000 and 400cm−1 with a resolution of 4cm−1 [21]. A Zeiss
SUPRA55-VP-typescanningelectronmicroscope(SEM)was
usedformicrostructureobservation.Tomaintainintegrityof
the aortic valve, measurements were performed at low volt-
age (1.4KV) and without the usual deposits of carbon at the
surface of the sample. Immunohistochemical analyses were
performed on formalin-ﬁxed samples. Paraﬃn-embedded
sections were stained with monoclonal mouse antihuman
primary antibodies against von Willebrand factor (Dako
reference A0082; dilution, 1:200), CD3 (Dako reference
F7.2.38; dilution, 1:100), CXCL12/SDF-1(RD system; clone
79018, dilution 1/30), CXCR4 (RD system; clone 12G5,
dilution 1/100) and polyclonal rabbit antihuman antibodies
againstCD117(DakoreferenceK0678;dilution,1:200),IL-6
(Abcam reference ab6672; dilution 1:400). According to the
manufacturer’s recommendations, DAKO LSAB kit k0673
was used for primary antibody detection and Fast Red TR
substrate system was the chromogen. We assessed immun
ohistochemical staining of endothelial cells (ECs) in three
anatomical compartments: EC of the leaﬂet surface (ECS),
EC of neovessels near calciﬁed areas (ECC), and EC of
neovessels distant to calciﬁed areas (ECN).
The study was approved and executed in compliance
with the institutional review board of the Piti´ e-Salpˆ etri` ere
Hospital and all subjects gave informed consent concerning
the use of tissue.
3.Results
3.1. Histopathology. The morphologic hallmarks of CAVD
were heaped-up calciﬁed masses within the aortic cusps that
protruded into the outﬂow surfaces. Calciﬁc deposits dis-
tortedthecuspalarchitecture, primarily atthebases. Thefree
cuspal edges were usually not involved. On the leaﬂet proﬁle
calciﬁcations were located within the valvular ﬁbrosa, at the
point of maximal cusp ﬂexion. Cusps were heavily ﬁbrosed
and frequently presented chronic inﬂammatory inﬁltrate
mainly consisting of lymphocytes, macrophages, and masts
cells. Sporadically, foreign body granulomas with giant cells
were present near calciﬁcations. Numerous blood microves-
sels within calciﬁed areas were observed in close association
to inﬂammatory inﬁltrates and frequentlydisposed in a nest-
like pattern (Figure 1(a)). Microvessels revealed diﬀerent
phenotypes with thin-walled capillary-like appearance or
thickened arteriolar wall structure. Intra- or extracellular
lipid depositions, as seen in arterial atheromatous lesions,
were not observed.The histological valvearchitecture distant
to calciﬁed areas was preserved. Histomorphological corre-
lates to calciﬁcation or microcalciﬁcation at this site were not
observed. However, cusps showed some ﬁbrous remodelling,
and few thin-walled capillary neovessels were present. The
control sample (Bentall surgery) grossly corresponded to a
normalvalveleaﬂetanatomywithasinglelayerofendothelial
cells lining the spongiosa layer on the aortic side with loosely
organized connective tissue and an elastin-rich ventricularis
layer on the ventricular side. Although aortic valves are con-
sidered as nonvascularized tissues, few capillary neovessels,
but no inﬂammatory inﬁltrates, were present on the control
sample. Calciﬁcations or major ﬁbrous remodeling were not
observed.
3.2.Immunohistochemistry. ECfromallsamples andfromall
compartments expressed vWF and CXCL12. CXCR4 expres-
sion was observed in ECC, while ECN and ECS were sporad-
ically stained or completely negative. IL-6 was expressed in
ECC and ECS, while mostly negative in ECN. The control
sample presented with a diﬀerent expression proﬁle: as by
deﬁnition, only ECN and ECS were present; while bothCardiology Research and Practice 3
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Figure 1: Immunohistochemical pattern of inﬂammatory inﬁltrate and neovascular endothelial cells in microscopically calciﬁed (ECC)
and noncalciﬁed (ECN) areas, as well as of surface endothelial cells (ECS) in aortic valves from patients with calciﬁc aortic stenosis. (a)
Hematoxylin-Eosin-Saﬀron staining, note multiple capillary neovessels near calciﬁed area (arrows); (b) CD3+ lymphocytes in the range of
neovessels (asterisks) near calciﬁc lesions; (c) CD117+ cells corresponding to mast cells are sparsely present. (d) Neovessels of all subgroups
are highlightened by FVIII staining (here: ECC) (e) CXCL12 (ECC); (f) CXCL12 (ECN); (g) CXCR4 (ECC); (h) CXCR4 (ECN); (i) IL-
6 (ECC); (j) VEGF in surface endothelial cells (arrows on ECS); (k) VEGFR (arrows on ECC); (l) VEGFR (arrows on ECN). Images
(a),(d),(f),(g),(h),(i),(j),and (k): magniﬁcation ×100; images (b),(c),(e), and (l): magniﬁcation ×200.
EC subgroups were easily detected by vWF expression and
stained for CXCL12, ECN were negative for IL-6, while ECS
moderately stained.
VEGF was constantly expressed in ECS of all valves and,
to a lesser extent, in ECC. VEGFR1 was expressed in both
ECC and ECN, while ECS was negative. ECN in the control
sample revealed expression of VEGFR1.
Inﬂammatory inﬁltrate in the range of neovessels mainly
revealed CD3+ lymphocytes and CD117+ mast cells. In an
attempt to diﬀerentiate mast-cells from CD117+ bone mar-
row-derived progenitor cells, slides were secondarily counter
stained with Toluidine-Blue; CD117-positive/Toluidine-neg-
ative cells were not observed. Immunohistochemical results
are presented in Figures 1(b)–1(l)4 Cardiology Research and Practice
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Figure 2: Scanning electron micrographs of crystalline ultrastructures on the surface of inconspicuous valve areas in patients suﬀering
from CAVD. (a) Bundles of faceted microrods are inserted into the leaﬂet surface. Magniﬁcation ×5790. (b) Surface areas are covered with
round-shaped or sphere-like, ﬂat structures adherent to the leaﬂet surface. Note the additional small bundle of plate-like facetted microrods
(center). Magniﬁcation ×1790.
3.3. Scanning Electron Microscopy. Scanning Electron Mi-
croscopy (SEM) analysis of the leaﬂet surface within non-
calciﬁed areas revealed the presence of two types of three-
dimensional crystal structures: we diﬀerentiated plate-like,
facetted microrods which were vertically inserted into the
endothelial surface, measuring approximately 10μm. These
heterogeneouslydistributedstructureswhere associated with
5–8μm large sphere- ornodule-like structures, focally cover-
ing the leaﬂet surface. The same ultrasctructural modiﬁca-
tionswere—to a lesser extent—present in the control sample
(Figures 2(a) and 2(b)). In contrast, calciﬁed areas massively
displayed large crystalline accumulations of 100μma n d
more, extensively covering the analyzed valve areas.
3.4. EDX Analysis. X-ray ﬂuorescence emission revealed
a signiﬁcant phosphor peak in calciﬁed and a small elevation
of phosphor in noncalciﬁed areas. No calcium peak was
noticeable for noncalciﬁed areas, whereas present in calciﬁed
regions. Light elements, such as carbonate, oxygen, and
sodium were present in both regions (Figure 3).
3.5. FT-IR Spectroscopy. Calcium apatite and amorphous
carbonated calcium phosphate were the major components
in grossly calciﬁed areas. Inconspicuous areas with crys-
talline ultrastructures only contained calcium apatite. Ap-
proximately 80% of the material in grossly calciﬁed areas
corresponded to calciumapatite, and 10% of calciumapatite
was found in grossly noncalciﬁed areas. Calcium apatite was
also present in the control sample (Bentall surgery). Higher
amountsoftriglycerideswereretrievedwithininconspicuous
valve areas, as compared to calciﬁc lesions (Table 1).
4.Discussion
In order to detect ultrastructural pathological transforma-
tions in valve structure, we analyzed noncalciﬁed and calci-
ﬁed areas of human aortic valves which had been surgically
removed due to symptomatic calciﬁc stenosis, as well as one
Table 1: Chemical composition of crystalline ultrastructures in
inconspicuous valve areas (HNCA) and in massive calciﬁcations of
the same samples (HCA) given by FT-IR: proportions of proteines
(Prot) and tendencially triclycerides (TGLs) are higher in areas
with crystalline ultrastructures. Carbonated calcium hydroxylap-
atite (CA) is present in inconspicuous areas, while amorphous
carbonated calcium phosphate (ACCP) is only present in massive
calciﬁcations. No signiﬁcant diﬀerences were found for cholesterol
(Chol) or whewellite (C1).
Samples CA ACCP Prot TGL Chol C1
HCA 1 59% 18% 20% 3% — —
HCA 2 47% 20% 20% 8% 5% —
HCA 3 56% 20% 20% 4% — —
HCA 4 57% 15% 20% 5% — 3%
HNCA 1 10% — 87% 3% — —
HNCA 2 11% — 75% 9% 5% —
HNCA 3 12% — 82% 6% — —
HNCA 4 5% — 90% 2% — —
Control 12% — 72% 12% 4% —
totally inconspicuous valve excised in the context of Bentall
surgeryinapatientwithnonatheroscleroticaorticaneurysm.
After histological study of the samples, we submitted them
to scanning electron microscopic and Fourier transform—
infrared spectroscopy in an attempt to eventually deﬁne an
elementary proﬁle indicating an initial change in structural
organization, possibly preceding manifest remodeling.
Our scanning electron micrographs suggest that crys-
talline ultrastructures of diﬀerent appearance are present on
the surface of histologically inconspicuous valve tissue. SEM
analysis allowed us to diﬀerentiate two types of crystalline
ultrastructures, within noncalciﬁed areas: we discriminated
smaller, spherical, or nodule-like structures partly cov-
ering the surface and accumulations of larger, plate-like
facetted microrods radially inserted into the valve leaﬂet.
Our observations match with the ultrastructural aspectCardiology Research and Practice 5
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Figure 3: EDX spectra collected for the ultrastructures presented
above (blue graph) and for massively calciﬁed lesions within the
same valve (red graph) (SEM not shown). The contributions of
light elements such as C (carbon), O (oxygen), and Na (sodium)
are predominating within crystalline ultrastructures, while massive
calciﬁcationsdisplay higher peaks of elements such as P (phosphor)
and Ca (calcium). Results are ﬁtting into the chemical composition
given by FT-IR (see beneath).
of typical biological apatites within calciﬁed lesions of
human aortic valves: a physochemical and ultrastructural
study by Mikroulis and coworkers of native aortic valves and
porcine aortic bioprostheses revealed two types of coexisting
valve deposits, that is, large (>20 micrometers) and medium
(5–20 micrometers) plate-like crystals as well as micro-
crystalline (<5 micrometers) calcium phosphate mineral
formations [22]. Their results suggest that the mineral salt
of calciﬁed valves is a mixture of calcium phosphate phases,
suchasdicalciumphosphatedihydrate(DCPD),octacalcium
phosphate (OCP), and hydroxyapatite (HAP). DCPD and
OCP are suggested to be precursor phases transformed to
HAP by hydrolysis. Of importance, the authors found a
lower value of the Ca/P molar ratio in the bioprostheses as
compared with native valves. This diﬀerence was ascribed
to a higher content of precursor phases, such as DCPD
and OCP in bioprosthetic valves, subsequently transformed
into HAP. In terms of ultrastructural morphology and
chemical composition we have found resembling pattern
within macroscopically inconspicuous valve areas. Notewor-
thy, Ca/P ratio was signiﬁcantly lower in macroscopically
noncalciﬁed areas, as compared to grossly calciﬁed lesions.
FT-IR results for the calciﬁed samples showed that calcium
apatite and amorphous carbonated calcium phosphate are
the major components in grossly calciﬁed areas. In contrast,
inconspicuous areas with crystalline ultrastructures only
contain calcium apatite, even though in diﬀerent propor-
tions: while approximately 80% of the material in grossly
calciﬁed areas is made of calcium apatite, 10% of calcium
apatite is found in inconspicuous areas. Of note, calcium
apatiteisalso presentin thecontrolsample (Bentallsurgery).
In addition, we observed at least comparable, if not slightly
higher, amounts of triglycerides within inconspicuous valve
areas, as compared with calciﬁc lesions. It is of note that
several studies dedicated to the morphology of triglyceride
crystals [23, 24] indicate that these ultrastructures present
a sphere-like or a layered pattern, similar to our leaﬂet
covering micronodules. Finally, our EDX spectra reveal the
presence of sodium in calciﬁed and in inconspicuous areas,
possibly signifying additional involvement of sodium urate
crystals. As expected, analysis of grossly calciﬁed aortic valve
areas showed important ultrastructural modiﬁcations with
large crystalline deposits of calciumapatite associated with
ﬁbrous remodeling. However, histological and ultrastruc-
turalmorphologyappearstobediscordantininconspicuous,
grossly noncalciﬁed valve areas. As stated above, our SEM
analysis revealed presence of facetted crystalline microrods
and layered micronodules on the leaﬂet surface. These
structures morphologically displayed tight adherence to the
endothelial surface and might in terms of ﬂow dynamics
represent a critical source of mechanical and/or oxidative
stress through ﬂow turbulences. In a recent study, Miller
andcoworkershavereportedsigniﬁcantlyincreasedoxidative
stress and altered antioxidant mechanisms in stenotic aortic
heart valves, as compared to normal heart valves [25]. Inter-
estingly, they have diﬀerentiated calciﬁed from noncalciﬁed
regions ofstenotic valves and foundsigniﬁcant dysregulation
of antioxidant enzymes superoxide dismutase (SOD) 1 and
3 in noncalciﬁed areas, suggesting that an impairment of
SOD upregulating mechanisms could contribute in a tissue
damaging increase of superoxide levels. Of note, endothelial
injury is considered as an early event in the formation of a
pathological calciﬁcation especially in the spongiosa layer on
the aortic side of the valve [26–28]. Further, previous studies
have reported endothelial cell dysfunction in apparently
calciﬁed aortic valves with deregulation of endothelial cell
markers such asICAM-1,VCAM-1, IL-6,and FVIII, suggest-
ing that endothelial cell dysfunction might to some extent be
present in early stages of disease evolution [29–32]. Inter-
estingly, Ewence and coworkers report a potential greater
risk for calcium phosphate micro- and nanoparticles in early
stages of atherosclerosis as compared to larger, radiologically
visibledepositsinmoreadvancedlesionsthroughaneﬀective
induction of various inﬂammatory pathways [33]a n di t
may be speculated that these inﬂammatory mediators are
expressed in the presence of valvular submicroscopic calci-
ﬁcations. However, our immunohistochemical experiments
revealed diﬀerent EC phenotypes, depending on the valve
area and its pathological remodeling: we observed constant
SDF-1 expression in EC from every compartment in human
calciﬁed aortic valves. In contrast, its receptor CXCR4 was
mainly expressed inmicrovessel accumulationsnear calciﬁed
nodules and to a lesser extent in leaﬂet lining endothelium.
Staining was inversely correlating with the distance to
calciﬁed areas. Interestingly a similar pattern was observed6 Cardiology Research and Practice
in the expression of the proinﬂammatory cytokine IL-6, with
prominent staining in EC near grossly lesioned valve areas. It
has been speculated that augmentation of CXCR4 signalling
in blood vessels near calciﬁcations induces proliferation of
neovessels and promotesinﬂammatory cellrecruitment from
blood [13–17]. The interplay of chronic inﬂammation and
tissue calciﬁcation has many similarities with atherosclerosis
of systemic arteries: the appearance and role of neoangio-
genesis in calciﬁed atheromas have been largely described
and are still controversially discussed by several groups
[34–36]. The formation of neovessels within a primary
inﬂammatory lesion is considered as an early event in CAVD
and might contribute to lesion progression by direct homing
ofinﬂammatory cellstowardsa chemokinegradient[18,37].
The pathomechanisms of endothelial cell recruitment and
neovessel organization within primary lesions remain to be
clariﬁed. Some investigators have detected signiﬁcant num-
bers of endothelial progenitor cells predominantly localized
within the valvular ﬁbrosa of calciﬁed valves, suggesting
that cells of extravalvular origin contribute to aortic valve
degeneration [38]. Others have suggested that recruitment
of circulating progenitor cells at the site of injured tissues
facilitates neovascularization through the VEGF/SDF-1 sys-
tem, both potent angiogenic factors [39]. In fact, it has been
shown that VEGF expression is increased in grossly calciﬁed
aortic valve tissue and associated with neovascularization, as
well as with expression of bone substrate proteins, such as
osteopontin and osteocalcin [33]. Our results conﬁrm that
VEGF is mainly expressed in endothelial cells of the leaﬂet
surface. Importantly, we found that its receptor VEGFR1 is
expressed in EC of neovessels near calciﬁed areas, as well
as in noncalciﬁed areas, suggesting an ongoing angiogenetic
loop within macroscopically bland areas with ultrastructural
crystalline deposits. Regarding the possible presence of pro-
genitor cells, our immunohistochemical experiments iden-
tiﬁed only granulated CD117-positive cells being toluidine-
positive, as well, and hence most probably corresponding
to masts cells and not to progenitor cells. Nevertheless,
manifest calciﬁc valve remodeling could be initiated after
a primary ultrasctructural event, through triggering of
inﬂammatory cascades orchestrated by cytokines, such as
IL-6 and subsequent pathologic angiogenesis via paracrine
activity of VEGF/SDF-1, ﬁnally rendering the lesion site
“active.”
The mechanism of CAVD remains largely unknown
compared to our understanding of the mechanisms under-
lying atherosclerotic diseases. We hypothesize that the SDF-
1/CXCR4and the VEGF/VEGFR system could have a pivotal
role in the initiation and development of CAVD. Our obser-
vations demonstrate that expression of SDF-1 and its recep-
tor CXCR4 is present in EC of pathologic microvessels.
Moreover expression of CXCR4 appears to correlate with
expression of IL-6, a cytokine with potent proinﬂammatory
activity in context of inﬂammation. Further more, we show
that a constant VEGF expression of leaﬂet surface ECs is
associatedwithVEGFR1expressionofECswithinpathologic
neovessels and that those neovessels are not exclusively
conﬁnedtocalciﬁedareas withinﬂammatory inﬁltrate but—
even if distributed in a sparse pattern—can be observed
in noncalciﬁed areas of diseased valves, as well as in non-
symptomatic valves lacking obvious calciﬁcation in light-
microscopy, but revealing endothelium-adherent crystalline
ultrastructures in SEM and IR spectrography.
The development of new pharmacologic therapies for
this disease requires a clearer understanding of the mecha-
nisms of disease onset. Angiogenic factors and proinﬂam-
matory cytokines are present and could represent an early
witness of subsequent inﬂammatory activity, ﬁnally leading
to ﬁbrous remodeling and symptomatic valvulopathy.
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